Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Bone marrow-derived mesenchymal stem cells (BM-MSCs) have shown beneficial effects in experimental colitis models, but the underlying mechanisms are not fully understood. We investigated the long-term effects of BM-MSCs, particularly in mice with chronic colitis. Methods: Chronic colitis was induced by administering 3% dextran sulfate sodium (DSS) in a series of three cycles. BMMSCs were injected intravenously into DSS-treated mice three times during the first cycle. On day 33, the therapeutic effects were evaluated with clinicopathologic profiles and histological scoring. Inflammatory mediators were measured with real-time polymerase chain reaction. Results: Systemic infusion of BM-MSCs ameliorated the severity of colitis, and body weight restoration was significantly promoted in the BMMSC- treated mice. In addition, BM-MSC treatment showed a sustained beneficial effect throughout the three cycles. Microscopic examination revealed that the mice treated with BM-MSCs had fewer inflammatory infiltrates, a lesser extent of inflammation, and less crypt structure damage compared with mice with DSS-induced colitis. Anti-inflammatory cytokine levels of interleukin-10 were significantly increased in the inflamed colons of BM-MSC-treated mice compared with DSS-induced colitis mice. Conclusions: Systemic infusion of BM-MSCs at the onset of disease exerted preventive and rapid recovery effects, with long-term immunosuppressive action in mice with repeated DSS-induced chronic colitis.
Abstract
Background/Aims: Bone marrow-derived mesenchymal stem cells (BM-MSCs) have shown beneficial effects in experimental colitis models, but the underlying mechanisms are not fully understood. We investigated the long-term effects of BM-MSCs, particularly in mice with chronic colitis. Methods: Chronic colitis was induced by administering 3% dextran sulfate sodium (DSS) in a series of three cycles. BMMSCs were injected intravenously into DSS-treated mice three times during the first cycle. On day 33, the therapeutic effects were evaluated with clinicopathologic profiles and histological scoring. Inflammatory mediators were measured with real-time polymerase chain reaction. Results: Systemic infusion of BM-MSCs ameliorated the severity of colitis, and body weight restoration was significantly promoted in the BMMSC- treated mice. In addition, BM-MSC treatment showed a sustained beneficial effect throughout the three cycles. Microscopic examination revealed that the mice treated with BM-MSCs had fewer inflammatory infiltrates, a lesser extent of inflammation, and less crypt structure damage compared with mice with DSS-induced colitis. Anti-inflammatory cytokine levels of interleukin-10 were significantly increased in the inflamed colons of BM-MSC-treated mice compared with DSS-induced colitis mice. Conclusions: Systemic infusion of BM-MSCs at the onset of disease exerted preventive and rapid recovery effects, with long-term immunosuppressive action in mice with repeated DSS-induced chronic colitis.
참고문헌 (35)
- Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
- Baumgart DC, "Inflammatory bowel disease: cause and immunobiology", Lancet, 369, pp.1627~1640 (2007)
- Bouma G, "The immunological and genetic basis of inflammatory bowel disease", Nat Rev Immunol, 3, pp.521~533 (2003)
- Baumgart DC, "Inflammatory bowel disease:clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)
- Torres J, "New therapeutic avenues in ulcerative colitis: thinking out of the box", Gut, 62, pp.1642~1652 (2013)
- Vermeire S, "Recent advances: personalised use of current Crohn’s disease therapeutic options", Gut, 62, pp.1511~1515 (2013)
- Drakos PE, "Case of Crohn’s disease in bone marrow transplantation", Am J Hematol, 43, pp.157~158 (1993)
- 김태일, "소화기질환에서의 줄기세포를 이용한 임상연구와 줄기세포 치료의 미래", 대한소화기학회지, 58(3), pp.139~143 (2011), 대한소화기학회
- Phinney DG, "Concise review: mesenchymal stem", multipotent stromal cells. The state of transdifferentiation and modes of tissue repair: current views, 2007, pp.25, 2896~2902
- De Miguel MP, "Immunosuppressive properties of mesenchymal stem cells: advances and applications", Curr Mol Med, 12, pp.574~591 (2012)
- 송인환, "Stem Cells in Inflammatory Bowel Disease New Potential Therapeutic Target", Intestinal research, 11(2), pp.79~84 (2013), 대한장연구학회
- García-Bosch O, "Review article: stem cell therapies for inflammatory bowel disease: efficacy and safety", Aliment Pharmacol Ther, 32, pp.939~952 (2010)
- Le Blanc K, "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells", Lancet, 363, pp.1439~1441 (2004)
- Fang B, "Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells", Bone Marrow Transplant, 38, pp.389~390 (2006)
- Gonzalez-Rey E, "Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis", Gut, 58, pp.929~939 (2009)
- Tanaka H, "Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat", J Gastroenterol, 46, pp.143~152 (2011)
- He XW, "Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice", Dig Dis Sci, 57, pp.3136~3144 (2012)
- Garcia-Olmo D, "Expanded adiposederived stem cells for the treatment of complex perianal fistula: a phase II clinical trial", Dis Colon Rectum, 52, pp.79~86 (2009)
- Duijvestein M, "Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study", Gut, 59, pp.1662~1669 (2010)
- Bruder SP, "Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells", J Orthop Res, 16, pp.155~162 (1998)
- Whittem CG, "Murine colitis modeling using dextran sulfate sodium (DSS)", J Vis Exp, 35, pp.e1652~ (2010)
- Williams KL, "Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone", Gastroenterology, 120, pp.925~937 (2001)
- Groux H, "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis", Nature, 389, pp.737~742 (1997)
- Boden EK, "Regulatory T cells in inflammatory bowel disease", Curr Opin Gastroenterol, 24, pp.733~741 (2008)
- Tse WT, "Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation", Transplantation, 75, pp.389~397 (2003)
- Prevosto C, "Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction", Haematologica, 92, pp.881~888 (2007)
- Strober W, "Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases", Gastroenterology, 140, pp.1756~1767 (2011)
- González MA, "Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses", Gastroenterology, 136, pp.978~989 (2009)
- Castelo-Branco MT, "Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis", PLoS One, 7, pp.e33360~ (2012)
- Strober W, "The immunology of mucosal models of inflammation", Annu Rev Immunol, 20, pp.495~549 (2002)
- Parekkadan B, "Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes", Gastroenterology, 140, pp.966~975 (2011)
- Izcue A, "Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation", Immunol Rev, 212, pp.256~271 (2006)
- Alex P, "Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBSinduced colitis", Inflamm Bowel Dis, 15, pp.341~352 (2009)
- Nguyen VH, "In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation", Blood, 109, pp.2649~2656 (2007)
- Perše M, "Dextran sodium sulphate colitis mouse model:traps and tricks", J Biomed Biotechnol, 2012, pp.718617~ (2012)